Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and HLX04 in advanced hepatocellular carcinoma
NCT03973112Phase 2Unknown
- Sponsor
- Henlius
- Start
- Sep 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in hepatocellular carcinoma (HCC), sponsored by Henlius. Status: unknown.
02
Drugs
serplulimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03973112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973112.